Vol 10, Supplement 13 (May 29, 2018): Journal of Thoracic Disease (Immunotherapy & Thoracic Cancers)

Preface

Immunotherapy & thoracic cancers
Antonio Rossi, Silvia Novello
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1425-S1426
.

Review Article

Is there a room for immune checkpoint inhibitors in early stage non-small cell lung cancer?
Elisa Gobbini, Matteo Giaj Levra
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1427-S1437
.
The role of radiology in the evaluation of the immunotherapy efficacy
Marco Calandri, Federica Solitro, Valeria Angelino, Federica Moretti, Andrea Veltri
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1438-S1446
.
Combining immunotherapy and radiotherapy in lung cancer
Neeraj Bhalla, Rachel Brooker, Michael Brada
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1447-S1460
.
Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?
Andrea Riccardo Filippi, Jacopo Di Muzio, Serena Badellino, Cristina Mantovani, Umberto Ricardi
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1461-S1467
.
Advanced non-small cell lung cancer: the role of PD-L1 inhibitors
David F. Heigener, Martin Reck
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1468-S1473
.
Lung cancer, elderly and immune checkpoint inhibitors
Francesca Casaluce, Assunta Sgambato, Paolo Maione, Alessia Spagnuolo, Cesare Gridelli
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1474-S1481
.
Immunotherapy in the Asiatic population: any differences from Caucasian population?
Lunxi Peng, Yi-Long Wu
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1482-S1493
.
Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios
Rebecca Tay, Arsela Prelaj, Raffaele Califano
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1494-S1502
.
Immune checkpoint inhibitors and small cell lung cancer: what’s new?
Sabine Schmid, Martin Früh
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1503-S1508
.
Thymic tumors and immune checkpoint inhibitors
Shintaro Yokoyama, Hiroaki Miyoshi
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1509-S1515
.
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients
Jordi Remon, Laura Mezquita, Jesús Corral, Noelia Vilariño, Noemi Reguart
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1516-S1533
.
Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors
Meng Qiao, Tao Jiang, Caicun Zhou
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1534-S1546
.
Oncogene-addicted non-small cell lung cancer and immunotherapy
Georgios Tsakonas, Simon Ekman
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1547-S1555
.
A review of guidelines for lung cancer
Paolo Bironzo, Massimo Di Maio
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1556-S1563
.
Do immune checkpoint inhibitors need new studies methodology?
Roberto Ferrara, Sara Pilotto, Mario Caccese, Giulia Grizzi, Isabella Sperduti, Diana Giannarelli, Michele Milella, Benjamin Besse, Giampaolo Tortora, Emilio Bria
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1564-S1580
.
Next generation immune-checkpoints for cancer therapy
Chiara Donini, Lorenzo D’Ambrosio, Giovanni Grignani, Massimo Aglietta, Dario Sangiolo
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1581-S1601
.
Vaccine and immune cell therapy in non-small cell lung cancer
Helena Oliveres, Christian Caglevic, Francesco Passiglia, Simona Taverna, Evelien Smits, Christian Rolfo
Journal of Thoracic Disease  
2018;
10
(Suppl 13)
:S1602-S1614
.

Disclosure:

The supplement “Immunotherapy & Thoracic Cancers” was commissioned by the Editorial office, Journal of Thoracic Disease without any sponsorship or funding. Antonio Rossi and Silvia Novello served as the unpaid Guest Editors for the supplement.